House Energy and Commerce Committee Democratic leaders urge FDA to advance clinical trial diversity efforts

Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate

Robert F. Kennedy Jr., President-elect Donald Trump’s choice for HHS secretary, is unfit for that role and should not be confirmed, 77 Nobel laureates said in a letter to members of the U.S. Senate.

December 13, 2024

Vol.50 No.46

By Yiqing Wang

Drugs & Targets

FDA approves durvalumab for LS-SCLC

FDA approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

December 13, 2024

Vol.50 No.46

News Analysis

What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”

Robert F. Kennedy Jr., an anti-vaccine activist whom Trump has chosen to run HHS, would have the capacity to roll back core public health protections, including protections for people with cancer, and dismantle research related to infectious diseases, public health experts warn.

December 06, 2024

Vol.50 No.45

By Claire Marie Porter

Drugs & Targets

FDA grants accelerated approval to zenocutuzumab-zbco for NSCLC and pancreatic adenocarcinoma

FDA has granted accelerated approval to zenocutuzumab-zbco (Bizengri) for adults

December 06, 2024

Vol.50 No.45

Capitol Hill

As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research

The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

The National Comprehensive Cancer Network updated its chronic myeloid leukemia treatment guidelines, recommending Scemblix (asciminib) for the treatment of adults with newly diagnosed Ph+ CML-CP as a category 1-preferred.

November 22, 2024

Vol.50 No.44

House Energy and Commerce Committee Democratic leaders urge FDA to advance clinical trial diversity efforts

YOU MAY BE INTERESTED IN

Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate

FDA approves durvalumab for LS-SCLC

What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”

FDA grants accelerated approval to zenocutuzumab-zbco for NSCLC and pancreatic adenocarcinoma

As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

Renew today!

Subscriber content

Never miss an issue!

Login

House Energy and Commerce Committee Democratic leaders urge FDA to advance clinical trial diversity efforts

YOU MAY BE INTERESTED IN

Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate

FDA approves durvalumab for LS-SCLC

What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted researchFormer FDA Commissioner Scott Gottlieb expresses “deep concerns”

FDA grants accelerated approval to zenocutuzumab-zbco for NSCLC and pancreatic adenocarcinoma

As Trump’s second term nears, Republican support for NIH is at a low pointBy stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

Never miss an issue!

Login

What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”

As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research